1,006
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Secukinumab in the therapy of psoriasis and psoriatic arthritis: a safe choice in clinical practice

References

  • Chiricozzi A. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis. Actas Dermosifiliogr. 2014; 105 Suppl1:9–20.
  • Lee E. Zarei M, La Senna C. et al. Psoriasis Targeted Therapy: Characterization of Interleukin 17A Expression in Subtypes of Psoriasis. J Drugs Dermatol 2015;14:1133–1136.
  • Lin AM, Rubin C, Khandpur R. et al. Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis. J Immunol 2011;187:490–500.
  • Lynde C, Poulin Y, Vender R, et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol 2014;71:141–150.
  • Schön MP, Erpenbeck L. The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis. Front Immunol 2018;9:1323.
  • Jack C, Mashiko S, Arbour N et al. Persistence of interleukin (IL)-17A + T lymphocytes and IL-17A expression in treatment-resistant psoriatic plaques despite ustekinumab therapy. Br J Dermatol 2017;177:267–270.
  • Van der Kerkhof P, Griffiths C, Reich K et al. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75:83–98.e4.
  • Bissonnette R, Luger T, Thaçi D et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol 2018;32:1507–1514.
  • Galluzzo M, Talamonti M, De Simone C et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther 2018;18:727–735.
  • Mease PJ, McInnes IB, Kirkham B et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329–39.
  • Kavanaugh A, Mease P, Reimold A et al. Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Follow up From a Phase III, Randomized, Double-Blind Placebo-Controlled Study. Arthritis Care Res 2017;69:347–355.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.